Royalty Pharma PLC（RPRX）の財務RPRXRoyalty Pharma PLC

Evaluating the bottom line, Royalty Pharma PLC maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.75%, while the net margin is 12.09%. These profitability ratios, combined with a Return on Equity (ROE) of 12.37%, provide a clear picture of how effectively RPRX converts its operational activities into shareholder value.

In the context of the broader market, RPRX competes directly with industry leaders such as BIIB and HLN. With a market capitalization of $36.72B, it holds a significant position in the sector. When comparing efficiency, RPRX's gross margin of 100.00% stands against BIIB's 65.46% and HLN's 66.10%. Such benchmarking helps identify whether Royalty Pharma PLC is trading at a premium or discount relative to its financial performance.

Royalty Pharma has demonstrated strong financial performance, with total revenue increasing from $593.64 million in Q4 2024 to $674.14 million in Q2 2026. The net income to common has also shown fluctuations, peaking at $294.69 million in Q1 2026, indicating solid profitability.